ORDER A TEST Log In Contact Us
Hero Background

PROVIDERS /// ONCOLOGY

Creating more options for your patients

Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.

CONTACT us

A comprehensive solution for all of your precision oncology needs

  1. GENOMIC PROFILING

    We deliver a comprehensive view of your patients through our tissue and liquid tests, DNA and RNA sequencing, somatic and germline tests, tumor-normal matched profiling and minimal residual disease and monitoring test options.
  2. ALGORITHMIC TESTS

    We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
  3. CLINICAL TRIAL MATCHING

    We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
  4. DIGITAL PATHOLOGY & AI

    We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
  5. FINANCIAL ASSISTANCE

    We are committed to making our tests accessible for those in financial need. Most applicants who qualify pay no more than $100.
  6. TEMPUS ONE

    The first generative AI-enabled clinical assistant that provides access to patient insights directly at your fingertips.
  7. TEMPUS+

    We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
  8. EHR INTEGRATION

    We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
  9. CARE PATHWAY SOLUTION

    We empower physicians to deliver the next step in a patient’s care journey with our AI-enabled care pathway intelligence platform.

Streamlining your workflow

One order. One platform. One financial assistance program.

Browse our FAQs

We have established relationships that span from community practices to more than 50% of all academic medical centers in the United States.

Open video in popup image description
Open video in popup image description
Working with the top hospitals in North America

In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.

Joseph K Hofmeister, MD, OhioHealth

Working with the top hospitals in North America

Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.

Megan Kruse, MD, Cleveland Clinic

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

  • ~7M

    de-identified research records

  • 20+

    operational countries across North, Central and South America, Europe, the Middle East, and Asia

image description

Our Science

view all publications
  • UPCOMING WEBINAR:

    Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan

    The presence of circulating tumor DNA can identify patients at higher risk of recurrence. Longitudinal surveillance of ctDNA may enable early identification of pts who are likely to relapse and presents a window of opportunity for early interventions to improve outcomes.

    Read more
  • UPCOMING WEBINAR:

    Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy

    There is an unmet need for a sensitive biomarker that can determine which patients will confer long term benefit from immune checkpoint inhibitors (ICI). While radiologic imaging is the current standard of care for assessing ICI response, imaging can be difficult to interpret and is typically only assessed at 3 month intervals. Here we evaluate the clinical benefit of a molecular biomarker, xM for treatment response monitoring (TRM), in addition to imaging.

    Read more
  • UPCOMING WEBINAR:

    TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment

    TriHealth’s EMR integration with Tempus AI TIME allows for patient screening using an AI powered software TApp that matches to a broad clinical trial portfolio. The goal of this collaboration is to increase TriHealth’s patients’ access for clinical trials.

    Read more
  • UPCOMING WEBINAR:

    Evolving From Discrete Molecular Data Integrations to Actionable Molecular Insights Within the Electronic Health Record

    As published in JCO Clinical Cancer Informatics, the commentary addresses the critical role of integrating molecular data into electronic health records (EHRs) for enhancing cancer treatment and personalized patient care. The authors outline challenges faced by clinicians in accessing and utilizing this data, despite recent technological advancements in AI and data interoperability that aid in its integration.

    Read more
  • UPCOMING WEBINAR:

    Development and validation of a deep learning-based microsatellite instability predictor from prostate cancer whole-slide images

    As published in npj Precision Oncology, we explore microsatellite instability-high (MSI-H), which is a tumor-agnostic biomarker for immune checkpoint inhibitor therapy. However, MSI status is not routinely tested in prostate cancer, in part due to low prevalence and assay cost. As such, prediction of MSI status from hematoxylin and eosin (H&E) stained wholeslide images (WSIs) could identify prostate cancer patients most likely to benefit from confirmatory testing to evaluate their eligibility for immunotherapy and need for Lynch syndrome testing.

    Read more
  • UPCOMING WEBINAR:

    A Circulating Tumor Fraction DNA Biomarker Response Stratified by ESR1 Mutation Status Correlates With Overall Survival in Patients With HR+ HER2- Metastatic Breast Cancer

    xF Monitor is a ctDNA assay that tracks changes in quantitative ctDNA TF and simultaneously monitors for the emergence of ESR1m, providing a diagnostic that identifies resistance to AI therapy and enables early switch to therapies that could improve outcomes in a patient population with poor prognosis.

    Read more

Featured News and Events

view all news
  • UPCOMING WEBINAR:

    Tempus Surpasses 500 Research Publications

    Tempus has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company’s multimodal data library.

    Read more
  • UPCOMING WEBINAR:

    Video: Harnessing the power of AI: Optimizing workflows & enhancing testing across the cancer care continuum

    Discover our latest technological advancements, such as One, Lens, Next and Link, that are helping to streamline efficiencies in clinical practices and research processes. With our most recent expansion into the MRD and monitoring space, we are leveraging these technologies to improve patient outcomes and surveillance strategies for both provider and biopharma partners.

    Watch replay
  • UPCOMING WEBINAR:

    Tempus Announces New Features to its Smart Physician Platform, Hub

    Tempus announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus unveils a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s comprehensive profiles to better inform care.

    Read more
  • UPCOMING WEBINAR:

    Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

    Tempus announces new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation sequencing assays.

    Read more
  • UPCOMING WEBINAR:

    Tempus Announces the Clinical Launch of its MRD Testing Portfolio

    Tempus announces the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies.

    Read more
  • UPCOMING WEBINAR:

    Video: ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies.

    Watch replay

Validations and Resources

view all resources
  • UPCOMING WEBINAR:

    Tempus xT Validation

    Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.

    Read more
  • UPCOMING WEBINAR:

    Tempus xF Validation

    Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.

    Read more
  • UPCOMING WEBINAR:

    Standard Requisition Form

    We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.

    View here

Partnering with Tempus is investing in the future

Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.